Kangxinuo: it is necessary to keep track of COVID-19 mutant. Bivalent COVID-19 mRNA vaccine is preparing for clinical trials.

[Kangxinuo: will carry out the necessary continuous tracking of the COVID-19 mutant COVID-19 mRNA vaccine is preparing for clinical trials] FAP, Kangxinuo Biological Co., Ltd. said in the recently disclosed record sheet of investor relations activities that the company will carry out the necessary continuous tracking of the COVID-19 mutant and consider the input-output ratio of related research and development. The company's bivalent COVID-19 mRNA vaccine consists of the company's first generation broad-spectrum COVID-19 mRNA vaccine and COVID-19 mRNA vaccine based on OmicronBA.4/5 mutants, which has been approved for clinical trials in April 2023 and is preparing for clinical trials.